He Yu: The first patient has been given FGFR2/3 inhibitor ABSK061 for the clinical trial of treating cartilage dysplasia.

In a announcement by Wu Yu-B, a subsidiary of the company, Shanghai Wuyu Biomedical Technology Co., Ltd., announced that its highly selective small molecule FGFR2/3 inhibitor ABSK061 has successfully completed the first patient dosing in a Phase II clinical trial for children aged 3-12 with cartilage development disorders.